To transpose our in vitro and animal data regarding the pro-steatotic effects of AAA-1 on hepatocytes, and to explore its relevance to CVD in humans, we analyzed the associations between AAA-1, NAFLD status (according to FLI), and CVD risk (according to 10-year FRS) [26] on 312 randomly selected PREVEND participants [22], and on the subgroup of individuals with a FLI ≥ 60, indicative of NAFLD [23–25]. The gene discussed is NPSR1-AS1; the disease is metabolic dysfunction-associated steatotic liver disease.